Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis
1. Two randomized clinical trials showed that intravenous ublituximab reduced relapse rate and the number of brain lesions in multiple ...
1. Two randomized clinical trials showed that intravenous ublituximab reduced relapse rate and the number of brain lesions in multiple ...
1. Registration for medical cannabis increased 4.5 times from 2016 to 2020 in the United States, with chronic pain and ...
1. This cohort study found that younger age, spinal cord involvement, and gadolinium-enhancing lesions on magnetic resonance imaging were associated ...
1. The use of highly effective disease-modifying treatments for relapsing-remitting multiple sclerosis was significantly more prevalent in Swedish patients compared ...
1. In recent years, the risk of persistent disability has been significantly reduced in patients with pediatric-onset multiple sclerosis (POMS), ...
1. Ponesimod was superior to teriflunomide for relapsing multiple sclerosis, in terms of reducing relapse rates, unique active lesions on ...
1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple ...
1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple ...
The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study 1. PPI use may ...
1. Increased serum neurofilament light chain levels, a biomarker for neuroaxonal damage, may be associated with a prodromal or subclinical ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.